The mechanism behind one of medicine's first approved Alzheimer's treatments has been a source of intense debate, with critics questioning whether amyloid-targeting drugs deliver meaningful benefits. New research reveals precisely how lecanemab works at the cellular level, potentially validating the amyloid hypothesis and informing next-generation dementia therapies.
The investigation demonstrates that lecanemab's therapeutic effect depends entirely on activating specialized immune cells called microglia in the brain. When researchers disabled the antibody's ability to engage these cells—while preserving its capacity to bind amyloid plaques—the drug lost all effectiveness. Single-cell analysis revealed lecanemab triggers a coordinated cellular program enhancing phagocytosis, lysosomal degradation, and metabolic reprogramming. The treatment specifically upregulates SPP1/osteopontin, a protein that proved essential for amyloid clearance when tested independently.
This mechanistic clarity addresses longstanding questions about anti-amyloid approaches in Alzheimer's disease. The finding that plaque binding alone proves insufficient—requiring active microglial engagement—explains why some earlier amyloid-targeting strategies failed. For aging adults concerned about cognitive decline, this research suggests effective Alzheimer's interventions must work through the brain's immune system rather than simply targeting pathological proteins. The study's identification of specific molecular pathways also opens possibilities for combination therapies that could enhance microglial function alongside amyloid removal, potentially improving outcomes for the 55 million people worldwide living with dementia.